Outro estudo mostrou que as terapias com anticorpos monoclonais neutralizantes não são eficazes quando administradas depois de o paciente já estar internado.

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial – The Lancet Infectious Diseases

Comentário convidado: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19